Here is a selection of people starting new roles with Waterways Ireland, IOB, Eaton, AbbVie Ireland, Deloitte Ireland and ...

AbbVie is eligible to receive tiered royalties on net sales ... PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and ...

Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative ColitisPRESS RELEASE – For UK consumer health, medical and trade media onlyRisankizumab will be ...

Oil prices rose to a three-month high on Friday on strong Chinese demand and concerns about dwindling US inventories. Brent ...

Who is Jason Hoppy? Discover the story of Bethenny Frankel's ex-husband, their high-profile marriage, and the turbulent ...

U.S. equities slumped at midday after the December jobs report came in higher than anticipated ... that wildfires in ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer ...

It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...